Eisai Co Ltd (JP:4523)
:4523
Want to see JP:4523 full AI Analyst Report?
4523 Stock Chart & Stats
¥4891.00
-¥56.00(-1.27%)
At close: 4:00 PM EST
¥4891.00
-¥56.00(-1.27%)
Day’s Range― - ―
52-Week Range¥3,832.00 - ¥5,349.00
Previous CloseN/A
Volume1.20M
Average Volume (3M)1.34M
Market Cap
¥1.20T
Enterprise Value¥1.13T
Total Cash (Recent Filing)¥245.42B
Total Debt (Recent Filing)¥186.08B
Price to Earnings (P/E)35.6
Beta0.98
Next Earnings
Jul 31, 2026EPS Estimate
58.23Next Dividend Ex-DateN/A
Dividend Yield3.51%
Share Statistics
EPS (TTM)136.74
Shares Outstanding291,649,140
10 Day Avg. Volume1,231,250
30 Day Avg. Volume1,336,443
Financial Highlights & Ratios
PEG Ratio-2.16
Price to Book (P/B)1.53
Price to Sales (P/S)1.66
P/FCF Ratio29.87
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
¥5,000.00Price Target Upside2.23% Upside
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)213.45
Revenue Forecast (FY)¥878.36B
Bulls Say, Bears Say
Bulls Say
High Gross MarginsSustained gross margins in the mid‑70s to ~80% are a durable competitive advantage for a specialty pharma. They provide pricing power and a structural buffer vs manufacturing or pricing pressure, enabling long‑term R&D funding and higher operating leverage as sales scale.
Conservative Leverage / Strong Balance SheetA conservative leverage profile with declining debt-to-equity gives Eisai financial flexibility to fund clinical programs, invest in commercialization, or pursue partnerships without heavy refinancing risk. This supports resilience through multi-year drug cycles and regulatory timelines.
Improving Cash GenerationA rebound to sustained positive operating and free cash flow across 2024–2026 improves Eisai's ability to self-fund R&D, sustain dividends, and execute strategic collaborations. Consistent cash generation supports long-term program investment despite episodic swings.
Bears Say
Cash Flow VolatilityMaterial year-to-year swings, including negative operating and free cash flow in 2023, raise execution risk for multi-year drug development. Volatility complicates planning for large, lumpy R&D or commercialization spends and weakens confidence in sustained organic funding sources.
Declining Net MarginsNet margins falling to roughly the mid-single digit range indicate margin pressure from cost, mix, or one-time items. Lower bottom-line conversion constrains retained earnings, limits reinvestment capacity, and raises sensitivity to revenue dips over multi-quarter cycles.
Moderate Returns On EquityA mid‑single digit ROE signals moderate efficiency in converting equity into profits. Over time, modest returns can cap shareholder upside absent faster growth or margin expansion, making it harder to justify aggressive capital deployment or to quickly improve valuation.
Eisai Co News
4523 FAQ
What was Eisai Co Ltd’s price range in the past 12 months?
Eisai Co Ltd lowest stock price was ¥3832.00 and its highest was ¥5349.00 in the past 12 months.
What is Eisai Co Ltd’s market cap?
Eisai Co Ltd’s market cap is ¥1.20T.
When is Eisai Co Ltd’s upcoming earnings report date?
Eisai Co Ltd’s upcoming earnings report date is Jul 31, 2026 which is in 71 days.
How were Eisai Co Ltd’s earnings last quarter?
Eisai Co Ltd released its earnings results on May 15, 2026. The company reported -¥11.53 earnings per share for the quarter, missing the consensus estimate of ¥6.443 by -¥17.973.
Is Eisai Co Ltd overvalued?
According to Wall Street analysts Eisai Co Ltd’s price is currently Undervalued.
Does Eisai Co Ltd pay dividends?
Eisai Co Ltd pays a Semiannually dividend of ¥80 which represents an annual dividend yield of 3.51%. See more information on Eisai Co Ltd dividends here
What is Eisai Co Ltd’s EPS estimate?
Eisai Co Ltd’s EPS estimate is 58.23.
How many shares outstanding does Eisai Co Ltd have?
Eisai Co Ltd has 291,649,140 shares outstanding.
What happened to Eisai Co Ltd’s price movement after its last earnings report?
Eisai Co Ltd reported an EPS of -¥11.53 in its last earnings report, missing expectations of ¥6.443. Following the earnings report the stock price went up 0.042%.
Which hedge fund is a major shareholder of Eisai Co Ltd?
Currently, no hedge funds are holding shares in JP:4523
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Eisai Co Ltd
Eisai Co., Ltd. offers pharmaceutical products in Japan. It offers Aricept for the treatment of alzheimer's disease/dementia with Lewy bodies; Methycobal for the treatment of peripheral neuropathy; and Fycompa, an antiepileptic drug for the adjunctive treatment of partial-onset and primary generalized tonic-clonic seizures. The company also provides Lyrica for pain treatment; Dayvigo, an anti-insomnia drug for the treatment of adults with insomnia; Lenvima, an anticancer agent/molecular targeted medicine for the treatment of thyroid cancer, renal cell carcinoma in combination with everolimus, and hepatocellular carcinoma; and Halaven, an anticancer agent/microtubule dynamics inhibitor for the treatment of breast cancer and liposarcoma. In addition, it offers Pariet, a proton-pump inhibitor for the treatment of gastric and duodenal ulcers, reflux esophagitis, and eradication of Helicobacter pylori infections, etc.; Humira, a fully human anti-TNF-a monoclonal antibody for the treatment of autoimmune diseases, such as rheumatoid arthritis; and Chocola BB plus, a vitamin B2 preparation for rough skin and stomatitis, as well as various products, which include third-class OTC drugs, designated quasi-drugs, and food with nutrient function. The company was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was incorporated in 1941 and is headquartered in Tokyo, Japan.
4523 Company Deck
4523 Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a strong performance of their global brands and significant global expansion of LEQEMBI, contributing to positive revenue growth. However, challenges in controlling cost of sales, slower-than-expected U.S. market expansion, and concerns about competitive threats were notable downsides.View all JP:4523 earnings summaries4523 Stock 12 Month Forecast
Average Price Target
¥5,000.00
▲(2.23% Upside)
Technical Analysis
Sumitomo Dainippon Pharma Co
―
Kaken Pharmaceutical Co
―
Shionogi & Co
―
Takeda Pharmaceutical Co
―
Nippon Shinyaku Co., Ltd.
―
Options Prices
Currently, No data available
---